Skip to main content

Table 1 Cardiovascular results of the Empa-Reg outcome study

From: The EMPA-REG outcome study: critical appraisal and potential clinical implications

  Empagliflozin (all together) Placebo HR 95 % CI Non inferiority Superiority
Primary endpoint 490/4687 (10.5 %) 282/2333 (12.1 %) 0.86
0.74–0.99
P < 0.001 P = 0.04
Key secondary endpoint 599/4687 (12.8 %) 333/2333 (14.3 %) 0.89
0.78–1.01
P < 0.001 P = 0.08
 Cardiovascular death 172/4687 (3.7 %) 137/2333 (5.9 %) 0.62
0.49–0.77
N.A. P < 0.001
 Non-fatal myocardial infarction 213/4687 (4.5 %) 121/2333 (5.2 %) 0.87
0.70–1.09
N.A. P = 0.22
 Non-fatal stroke 150/4687 (3.2 %) 60/2333 (2.6 %) 1.24
0.92–1.67
N.A. P = 0.16
Heart failure 126/4687 (2.7 %) 95/2333 (4.1 %) 0.65
0.50–0.85
N.A. P = 0.002
All-cause death 269/4687 (5.7 %) 194/2333 (8.3 %) 0.68
0.57–0.82
N.A. P = 0.001
  1. Primary endpoint: standard 3 endpoint-MACE (CV death, non-fatal myocardial infarction (MI), non-fatal stroke); pre-specified key secondary endpoints: time to first event (CV death, non-fatal MI, non-fatal stroke, hospitalization for unstable angina)
  2. N.A. not applicable